Oscar Tahuahua, Medical Oncology Fellow at the National Cancer Institute of Mexico, shared a post on X:
“Prospective, multicenter study in men ≥70 yrs with metastatic PC. Baseline cognitive impairment was present in 51% of pts receiving ADT + ARPI vs 26% with ADT alone & 10% in controls.
After ARPI initiation, attention & processing speed declined at 3–12 months (p<0.01), global decline was uncommon (<6%) but clinically meaningful. Supporting routine cognitive assessment when starting ARPIs in older pts.”
Title: Impact of androgen receptor pathway inhibitors on cognitive function in older adults treated for metastatic prostate cancer
Authors: Antoine Boué, Giulia Baciarello, Emmanuel Meyer, François Christy, Nedjla Allouache, Raffaele Ratta, Philippe Beuzeboc, Pierre-Emmanuel Brachet, Estelle Guerdoux, Amélie Darlix, Mathieu Boone, Sophie Gouerant, Alexandra Leconte, Justine Lequesne, Bénédicte Clarisse, Karim Fizazi, Marie Lange, Florence Joly
Read the Full Article.
More posts featuring Oscar Tahuahua.